Biparametric Prostate MRI Research Articles

UP49 - Comparison between biparametric prostate MRI (bpMRI) and multiparametric MRI (mpMRI) in the detection of prostate cancer

UP49 - Comparison between biparametric prostate MRI (bpMRI) and multiparametric MRI (mpMRI) in the detection of prostate cancer

UP43 - Diagnostic performance of biparametric prostate MRI in the detection of prostate cancer: focus on role of PSA, tumor volume and ADC in PI-RADS >= 4 nodules

UP43 - Diagnostic performance of biparametric prostate MRI in the detection of prostate cancer: focus on role of PSA, tumor volume and ADC in PI-RADS >= 4 nodules

Diagnostic value of radiomics based on biparametric prostate MRI imaging in Gleason classification of prostate cancer

Objective To explore the value of radiomics in stratifying the Gleason score (GS) of prostate cancer based on vast image features from biparametric MRI. Methods Three hundred and sixteen patients were enrolled in this study from October, 2015 to December, 2018 and their results of surgical pathology were obtained. The lesions were manually depicted by 3D-Slicer. Then, 106-dimensional features extracted by radiomics were used to conduct Spearman non-parametric correlation test with the high and low risk stratification of GS. The constructed Neural Network was trained with the features after dimension reduction by principal component analysis as the input. Then, the testing set was fed in to get the predictive capability of the model. In the end, 10-fold cross-validation and shuffle of 100 times were used to test the accuracy of the prediction and the generalization ability of the model. Results Seventy seven-dimensional features with significant correlation were found at the level of P valued=0.05 (two-tailed). After dimensional features were reduced, 21 dimensional new feature spaces with 99% original feature information were obtained. The results on the testing data after the 10-fold validation and shuffle were AUC=0.712 with T2WI, AUC=0.689 with DWI (b=1 000 s/mm2), AUC=0.689 with DWI (b=2 000 s/mm2) and AUC=0.691 with DWI (b=3 000 s/mm2). Conclusion The neural network after extracting features from biparametric MRI images can accurately and automatically distinguish the high risk and low risk groups of Gleason grade of prostatic cancer. Key words: Prostatic neoplasms; Magnetic resonance imaging; Radiomics

SC305 - Comparison between biparametric prostate MRI (bpMRI) and multiparametric MRI (mpMRI) in the detection of prostate cancer

SC305 - Comparison between biparametric prostate MRI (bpMRI) and multiparametric MRI (mpMRI) in the detection of prostate cancer

SC306 - Diagnostic performance of biparametric prostate MRI in the detection of prostate cancer: Focus on role of PSA, tumor volume and ADC in PI-RADS ≥ 4 nodules

SC306 - Diagnostic performance of biparametric prostate MRI in the detection of prostate cancer: Focus on role of PSA, tumor volume and ADC in PI-RADS ≥ 4 nodules

Update on Gadolinium-Based Contrast Agent-Enhanced Imaging in the Genitourinary System.

OBJECTIVE. The purpose of this article is to review gadolinium-based contrast agent (GBCA)-enhanced MRI applications in the genitourinary system. CONCLUSION. Nephrogenic systemic fibrosis is rare or nonexistent with standard dosing of group II GBCAs. Gadolinium retention, cost, and examination times are emerging considerations affecting GBCA use. GBCA is unnecessary to diagnose adrenal adenomas, simple cysts, and some Bosniak category II cysts; however, it is required to determine solid or septal renal mass enhancement. Biparametric prostate MRI requires high-quality and reproducible DWI; therefore, dynamic contrast-enhanced MRI remains valuable in selected prostate MRI examinations.

IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy.

Prostate MRI is increasingly being used in men with a clinical suspicion of prostate cancer (PCa). However, development and validation of methods for focal therapy planning are still lagging. To evaluate the diagnostic accuracy on lesion, region-of-interest (ROI), and voxel level of IMPROD biparametric prostate MRI (bpMRI) for PCa detection in men with a clinical suspicion of PCa who subsequently underwent radical prostatectomy. Prospective single-institution clinical trial (NCT01864135). Sixty-four men who underwent radical prostatectomy after IMPROD bpMRI performed in prebiopsy settings. IMPROD bpMRI consisted of T2 -weighted imaging (T2 w) and three separate diffusion-weighted imaging acquisitions with an average acquisition time of 15 minutes. The diagnostic accuracy of prospectively reported manual cancer delineations and regions increased with 3D dilation were evaluated on the voxel level (volume of 1.17 mm3 , 1 mm3 , 125 mm3 ) as well as the 36 ROI level. Only PCa lesions with a diameter ≥ 5 mm or any Gleason Grade 4 were analyzed. All data and protocols are freely available at: http://petiv.utu.fi/improd STATISTICAL TESTS: Sensitivity, specificity, accuracy. In total, 99 PCa lesions were identified. Forty (40%, 40/99) had a Gleason score (GS) of >3 + 4. Twenty-eight PCa lesions (28%, 28/99) were missed by IMPROD bpMRI, three (7.5%, 3/40) with GS >3 + 4. 3D dilation of manual cancer delineations in all directions by ~10-12 mm (corresponding to the Hausdorff distance) was needed to achieve sensitivity approaching 100% on a voxel level. IMPROD bpMRI had a high sensitivity on lesion level for PCa with GS >3 + 4. Increasing 3D lesion delineations by ~10-12 mm (corresponding to the Hausdorff distance) was needed to achieve high sensitivity on the voxel level. Such information may help in planning ablation therapies. 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:1641-1650.

Effectiveness of Bi-Parametric MR/US Fusion Biopsy for Detecting Clinically Significant Prostate Cancer in Prostate Biopsy Naïve Men.

PurposeTo explore the effect of bi-parametric MRI-ultrasound (MR/US) fusion prostate biopsy on the detection of overall cancer and significant prostate cancer (sPCa).Materials and MethodsWe examined 140 patients with suspected prostate cancer lesions on MRI from August 2016 to March 2018. All patients had undergone 3T pre-biopsy bi-parametric (T2 weighted and diffusion-weighted) prostate MRI (bpMRI), and their MRI images were evaluated with Prostate Imaging Reporting and Data System (PI-RADS) version 2.0. MR/US fusion targeted prostate biopsy was performed for lesions with a PI-RADS score ≥3 before systemic biopsy. The results of targeted and systemic biopsy were evaluated in regards to detection rate according to PI-RADS score.ResultsOf the patients (mean age=67.2 years, mean prostate-specific antigen level=8.1 ng/mL), 66 (47.1%) and 37 (26.4%) patients were diagnosed with cancer and significant prostate cancer, respectively. The rate of positive targeted biopsy increased with higher PI-RADS score (3: 40.4%, 4: 56.7%, 5: 90.0%). The proportion of significant prostate cancer among positive target lesions was 65.3% (32/49).ConclusionbpMRI is a feasible tool with which to identify sPCa. MR/US fusion biopsy, rather than systemic biopsy, can help identify sPCa. We recommend using supplemental tools to increase prostate cancer detection in patients with PI-RADS 3 lesions.

Simplified Prostate Imaging Reporting and Data System for Biparametric Prostate MRI: A Proposal

We describe our institutional experience using a simplified Prostate Imaging Reporting and Data System (PI-RADS) based on biparametric prostate MRI. We discuss two important controversies: the use of gadolinium-based contrast agents and the management of PI-RADS category 3 lesions. Our simplified PI-RADS identifies four categories and suggests management strategies for each. The simplified PI-RADS can be an effective system to facilitate multidisciplinary cooperation and to improve the management of suspected prostate cancer.